Literature DB >> 1711075

Antibody MT3 is reactive with a novel exon B-associated 190-kDa sialic acid-dependent epitope of the leukocyte common antigen complex.

S Poppema1, R Lai, L Visser.   

Abstract

MT3 is a new antibody reactive with a restricted isoform of the leukocyte common Ag (CD45) family. The Ag is mainly expressed on T lymphocytes and thymocytes. It is differentially expressed on B cell subpopulations, with no staining of the majority of small follicular mantle zone B cells but positive staining of the majority of marginal zone B cells of spleen. Like most CD45 antibodies, reactivity can be demonstrated in fresh frozen as well as in formalin-fixed, paraffin-embedded tissues. This reactivity clearly differs from all other published anti-CD45 antibodies. In immunoprecipitation and Western blot procedures, the antibody reacts with a major band with a molecular mass of 190 kDa and weak bands with molecular masses of 205 and 220 kDa. Compared to antibody PD7 that reacts with exon B-encoded sequences, the reactivity with the 205 and 220 bands is much weaker. This is reflected in MT3 reactivity with leukocyte common Ag transfectants that include exon B-encoded sequences, such as AB and B, but not with those that also include C-encoded sequences, such as ABC or BC. It can be concluded that MT3 recognizes additional heterogeneity in the leukocyte common Ag complex, that is based on the differential expression of sialic acid-dependent determinants associated with exon B-encoded sequences.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1711075

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  2 in total

1.  Monoclonal antibody OPD4 is reactive with CD45RO, but differs from UCHL1 by the absence of monocyte reactivity.

Authors:  S Poppema; R Lai; L Visser
Journal:  Am J Pathol       Date:  1991-10       Impact factor: 4.307

2.  Carbohydrate specificity of IgM autoantibodies to CD45 in systemic lupus erythematosus.

Authors:  P D Fernsten; J K Czyzyk; T Mimura; J B Winfield
Journal:  Mol Biol Rep       Date:  1994       Impact factor: 2.316

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.